Datasets for 2011 and 2012 only included data for antimicrobial VMPs imported by wholesalers, so sales of antimicrobial VMPs to end users by national manufacturers were not accounted for. Since 2013, antimicrobial VMPs produced by national manufacturers have also been dispensed by wholesalers. Thus, for the years 2013 to 2018, the data include sales from wholesalers to end users (pharmacies, retailers, veterinarians, farmers and feed mills), covering both import data and antimicrobial VMPs.
produced by national manufacturers. This difference in coverage is thought to be the main explanation for differences in sales between 2011 and 2012, and 2013 and 2018. Thus, data for the period 2012-2013 are not comparable with data for 2013-2018. For the period 2013-2018, which has the same data coverage, a 17% reduction in sales can be seen. Slovak manufacturers of veterinary medicinal products mainly produce products with tetracyclines, penicillins, sulfonamides, pleuromutilins and fluoroquinolones, which are the most-sold classes.

Sales (imports in 2011 and 2012), in mg/PCU, of 3rd- and 4th-generation cephalosporins declined from 2011 to 2018; in 2011, this subclass accounted for 1.5% of total sales; in 2018, the figure was 0.9%. In 2018, sales of 3rd- and 4th-generation cephalosporins were 0.44 mg/PCU, while aggregated sales for 25 countries in that year were 0.18 mg/PCU.

In Slovakia, sales of fluoroquinolones fluctuated from 2011 to 2018. In 2011 and 2018, the proportion of the total sales for this subclass accounted for 6.8% and 6.0%, respectively. In 2018, sales of fluoroquinolone VMPs were 2.98 mg/PCU. Aggregated sales for 25 countries in that year were 2.42 mg/PCU.

Sales (mg/PCU) of other quinolones decreased by 93% from 2011 to 2018; in 2011, this subclass accounted for 0.75% of the total sales, while in 2018 this figure was 0.05%. In 2018, sales of other quinolones were 0.02 mg/PCU, while the aggregated sales for 25 countries in that year were 0.27 mg/PCU.

Sales (mg/PCU) of polymyxins fluctuated during the study period. In 2018, they were 1.36 mg/PCU, while aggregated sales for 25 countries in that year were 3.31 mg/PCU.